AUTHORS
Barbara Peixoto, PhD, Xiaoqing Yu, PhD2, Michael D. Jain, MD, PhD3, Meghan A. Menges4, Julieta Abraham-Miranda5, Joel Turner, PhD6, Jerald D. Noble, PhD7, Salvatore Corallo, BS8, Julia Llanos, BS9, Luis A. Cuadrado, MSc10, William Sawyer11, Emily C. Merritt12, Reginald Atkins, PhD13, Frederick L. Locke, MD14
AFFILIATIONS
1 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
12 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
13 H. Lee Moffitt Cancer Center, Tampa, Florida, United States
14 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States, H. Lee Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
CD39 expression increases in tumor-associated T cells and is linked to an immunometabolically dysfunctional/exhausted phenotype characterized by PD-1 and TIGIT co-expression. We previously reported (Jain, ASH 2023) that increased frequencies of CD8⁺CD39⁺ leukapheresis T cells were associated with high tumor burden, lower inosine levels, and inferior outcomes after CD19 CAR-T therapy for large B-cell lymphoma (LBCL). Additional analysis revealed associations between CD39 expression, increased docosahexaenoic acid (DHA) (r=0.55, p=0.01), and reduced cysteinylglycine (Cys-Gly) (r=0.47, p=0.03), implicating dysregulated purine and redox metabolism. We hypothesized that circulating factors associated with systemic inflammation and metabolic dysregulation could directly promote CD39 expression.
In a larger LBCL cohort (n=117) high CD39 expression on either CD4+ or CD8+ leukapheresis T cells was associated with lack of ongoing remission at 12 months (p=0.029 and p=0.001, respectively). High CD8+CD39+ frequencies were also associated with ferritin >400 ng/mL (p=0.007) and CRP >4 mg/dL (p=0.029), inflammatory biomarkers previously associated with inferior CAR-T outcomes.
To determine whether circulating factors directly remodel T-cell phenotype, healthy donor T cells were activated in plasma-like medium supplemented with physiologic glucose levels and 20% serum from 36 individual patients. Multiparameter flow cytometry demonstrated differential induction of CD39, GLUT1, CD71, and PD-1 (all p<0.005). Across serum conditions, CD39 correlated with GLUT1 (r=0.73, p<0.001), A2AR (r=0.81, p<0.001), and TIGIT (r=0.53, p<0.05), linking CD39 to a metabolically remodeled inhibitory state.
To test whether oxidative stress directly induces CD39, activated healthy donor T cells were exposed to H₂O₂. Oxidative stress increased CD39 expression (p≤0.001) and reduced mitochondrial membrane potential (p<0.05), implicating redox stress in CD39 induction.
To determine whether lipid peroxidation contributed to these effects, healthy donor CAR-T cells were manufactured in the presence of patient serum with or without Liproxstatin-1 (Lip-1). Lip-1 reduced CD39 expression and enhanced cytotoxicity (p≤0.05), although responses varied among sera, suggesting lipid peroxidation contributes to both phenotypic and functional consequences of the patient serum environment.
Together, these findings support a model in which the pre-leukapheresis systemic inflammatory and metabolic environment promotes development of a CD39+ dysfunctional T-cell state. Oxidative stress and lipid peroxidation emerge as candidate mechanisms linking systemic inflammation to impaired CAR-T starting material quality.
DISCLOSURES
Barbara Peixoto, PhD: No relevant conflicts of interest to declare.